PMPRB Summary of VCUs & Orders - 2003
Click on medicine to view details of VCU
| DATE OF APPROVAL |
MEDICINE |
PATENTEE |
%Above Guidelines |
PRICE REDUCTION1 |
EXCESS REVENUES2 |
PAYMENTS |
PATENT STATUS |
| VCUs |
| October 21, 2003 |
Dostinex |
Pfizer Canada Inc. |
|
|
$42,116.31 |
$42,116.31 |
Expired 11/2000 |
| April 26, 2003 |
Aromasin |
Pharmacia Canada Inc. |
15.6 - 5.5 |
See VCU for details |
$87,484.65 |
By price reduction |
|
| March 31, 2003 |
Remicade12 |
Schering Canada Inc. |
|
Yes - by 20% |
$7,792,650.89 |
$7,792,650.89 |
|
| ORDER |
1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.
2. In all cases, all excess revenues were offset through further price reduction and/or payment.
12. Notice of Hearing issued on December 16, 2002.